Author:
Courtney R.,Sansone A.,Smith W.,Marbury T.,Statkevich P.,Martinho M.,Laughlin M.,Swan S.
Subject
Pharmacology (medical),Pharmacology
Reference25 articles.
1. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592);Manavathu;J Antimicrob Chemother,2000
2. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans;Pfaller;Antimicrob Agents Chemother,2001
3. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000;Pfaller;Antimicrob Agents Chemother,2002
4. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes;Sun;Antimicrob Agents Chemother,2002
5. Hachem RY Raad II Afif CM et al. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections (IFI) refractory (R) to or intolerant (I) to standard therapy (ST) [abstract]
Cited by
115 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献